Pear Therapeutics to Participate in the BTIG Digital Health Forum
10 Novembre 2022 - 2:00PM
Business Wire
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing
and commercializing software-based medicines called prescription
digital therapeutics (PDTs), today announced management’s
participation in the virtual BTIG Digital Health Forum being held
on Monday, November 21. Corey McCann, M.D., Ph.D., President and
CEO, will participate in a fireside chat at 10:00 a.m. ET.
BTIG hosted events are intended for prospective and existing
BTIG clients only. To listen to the live event, please contact your
BTIG representative with interest.
About Pear Therapeutics Pear Therapeutics, Inc., which is
traded on Nasdaq as PEAR, is the parent company of Pear
Therapeutics (US), Inc. Pear is the leader in developing and
commercializing software-based medicines, called prescription
digital therapeutics (PDTs). Pear aims to redefine care through the
widespread use of clinically validated software-based therapeutics
to provide better outcomes for patients, smarter engagement and
tracking tools for clinicians, and cost-effective solutions for
payers. Pear has the first end-to-end platform to discover,
develop, and deliver PDTs to patients and a pipeline of products
and product candidates across therapeutic areas., including the
first three PDTs with disease treatment claims from the FDA. Pear’s
product, reSET®, for the treatment of substance use disorder, was
the first PDT to receive marketing authorization from the FDA to
treat disease. Pear’s second product, reSET-O®, for the treatment
of opioid use disorder, was the first PDT to receive Breakthrough
Designation. Pear’s third product, Somryst® for the treatment of
chronic insomnia, was the first PDT submitted through FDA’s
traditional 510(k) pathway while simultaneously reviewed through
FDA’s Software Precertification Pilot Program. For more
information, visit Pear at www.peartherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221110005213/en/
Media and Investors: Meara Murphy Senior Director,
Corporate Communications meara.murphy@peartherapeutics.com
Pear Therapeutics (NASDAQ:PEAR)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Pear Therapeutics (NASDAQ:PEAR)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Pear Therapeutics Inc (NASDAQ): 0 recent articles
Plus d'articles sur Pear Therapeutics Inc